abstract: Empty follicle syndrome is a condition in which no oocytes are retrieved after an apparently adequate ovarian response to stimulation and meticulous follicular aspiration. It is a rare condition of obscure etiology. A patient with primary infertility who underwent seven assisted reproductive technique cycles is described. In spite of a satisfactory ovarian response, aspiration yielded no oocytes in four cycles and 1-4 low quality oocytes in three cycles. In the index treatment cycle, ovulation was triggered using GnRH agonist 40 h prior to ovum pickup and hCG was added 6 h after the first trigger. Eighteen oocytes were recovered, of which 16 were mature and were inseminated by ICSI. Two embryos were transferred 48 h after aspiration and nine embryos were cryopreserved. The patient conceived and delivered a healthy boy at 38 weeks of gestation. The literature is reviewed and possible etiologies and treatment options of this enigmatic syndrome are suggested.
Introduction
Empty follicle syndrome (EFS) was first described by Coulam et al. (1986) . It is a condition in which no oocytes are retrieved after an apparently adequate ovarian response to stimulation and meticulous follicular aspiration. EFS in the presence of dominant follicles is an uncommon event, estimated to occur in 0.045-3.5% of patients undergoing ovum pickup (OPU) (Ben-Shlomo et al., 1991; Awonuga et al., 1998; Driscoll et al., 1998; Zreik et al., 2000; Aktas et al., 2005; Coskun et al., 2010; Mesen et al., 2011; Castillo et al., 2012) .
EFS has been classified into 'genuine' (GEFS) and 'false' EFS (FEFS). The former was defined as a failure to retrieve oocytes from mature ovarian follicles after ovulation induction and apparently normal follicular development and steroidogenesis in the presence of optimal b-hCG levels on the day of oocyte retrieval. The latter was defined as a failure to retrieve oocytes in the presence of low b-hCG due to an error in the administration, or the reduced bioavailability, of choriogonadotrophin (Stevenson and Lashen, 2008) .
The underlying mechanism of GEFS remains obscure. Some have even cast doubt regarding the existence of the syndrome (Ben-Shlomo et al., 1991; Harrison and Fawzy, 1996) .
In this report, we present a patient who underwent four OPUs in which no oocytes were aspirated. In three other cycles, the aspiration yielded between one and four low quality oocytes. Changing the treatment protocol brought about a successful outcome. We also review the literature about this debated syndrome.
Patients and Methods

Case report
A couple with primary infertility of 25 months presented to our fertility clinic in 2003. The 24-year-old patient had irregular menses since menarche at the age of 12, with maximal amenorrhea periods of 50 days. Her BMI was 26. Physical examination was unremarkable with no acne or hirsutism. Pelvic sonography revealed normal pelvic findings with 8 mm regular endometrium and a 20 mm ovarian follicle. The early follicular phase hormone profile was normal and FSH was 4.89 IU/l. Previously, prolactin was slightly elevated and a computerized tomography scan demonstrated a 6 mm structure suspected to be a microadenoma, although the patient never received anti-dopaminergic treatment; all her subsequent prolactin levels were normal. Hysterogalpingography was unremarkable.
Owing to a family history, coagulation tests were done and the patient was found to be heterozygote for the prothrombin mutation (FII G20210A) and homozygote for MTHFR (C677T mutation). Treatment with folic acid 5 mg/day was advised.
The husband was a 28-year-old truck driver who smoked 30 cigarettes/ day. Physical examination revealed third degree varicocele. Sperm analysis demonstrated oligo-asthenozoospermia (13 M/ml, 40% motility). He subsequently underwent subinguinal ligation of the spermatic vein.
The couple returned to our clinic 9 months later, since no spontaneous pregnancy was achieved. Ovulation induction with clomiphene citrate (two cycles) or gonadotrophins (two cycles), combined with IUI, was carried out. Despite a normal ovarian response and a total count of 3 -10 million motile spermatozoa per insemination, pregnancy was not achieved. In the years 2005 -2011, the patient went through eight assisted reproductive technique (ART) cycles, described in Table I . Low molecular weight heparin (Enoxaparin 40 mg/day, Sanofi Winthrop Industrie) was added concomitant with ovarian stimulation because of the hypercoagulabile state. Ovarian response was adequate, according to estradiol (E 2 ) levels and sonographic appearance, but no oocytes were aspirated in four cycles. In one of the cycles, but not in others, high progesterone levels indicated premature lutealization as a possible cause for the failure to retrieve oocytes. Quantitative b-hCG levels were obtained on two occasions after the failed retrievals and found to be 44 and 70 IU/l. Three additional cycles yielded between one and four oocytes, only two of which were mature and were injected. No embryos were ever available for transfer. The patient underwent chromosomal analysis which showed a normal female karyotype.
In the last and finally successful cycle, we chose to administer a GnRH agonist (Triptorelin acetate, decapeptyl 0.1 mg*2, Ferring Pharmaceuticals Israel) 40 h prior to OPU. In order to avoid the unfavorable clinical pregnancy rate reported in similar protocols, recombinant hCG (Choriogonadotropin alfa, ovitrelle 250 mg, Serono) was given 34 h prior to OPU. Aspiration yielded 18 oocytes, 16 of them were mature oocytes which were injected. A total of 11 embryos developed; 2 were transferred 48 h after OPU and 9 were cryopreserved. Luteal support with progesterone (Endometrin 100*2/day, Ferring Pharmaceuticals Israel) and E 2 (Estrofem 2 mg*2/day, Novo Nordisk) was initiated on the day of embryo transfer. A singleton pregnancy was achieved and a healthy 2600 g boy was delivered at 38 weeks of gestation.
Literature search
MEDLINE was searched using the phrase 'EFS' no restrictions (language or other) were placed. The search yielded 60 citations. The reference lists from all citations were examined to identify cited articles not captured by electronic search, revealing 11 additional references. After this, nine studies were excluded for the following reasons: two were not in English, one described a case of a menopausal woman, one is a reply letter with the same data as described elsewhere, in two articles EFS was mentioned in a general discussion about infertility without specific consideration and three citations described sonographic assessment of EFS without follicle aspiration. All together, the 62 papers included were 43 case reports or case series, 10 observational studies, 3 reviews and 6 letters or comments.
In this study, 117 cases of EFS were described (Table II) . Only in 29 cases, positive hCG levels at OPU confirmed the diagnosis of GEFS. In 15 articles, data are presented on the prevalence of the syndrome (Table III) . These studies add 487 more cases of EFS, of which 28 were genuine.
Discussion
Definitions EFS is an uncommon, complex and frustrating phenomenon in which no oocytes are retrieved after ovarian stimulation, despite apparently normal follicular development and E 2 levels. It is classified as 'genuine' in the presence of optimal hCG levels on the day of oocyte retrieval and 'false' when the levels are low (Stevenson and Lashen, 2008) . Optimal hCG levels are not unequivocally defined. Aktas et al. (2005) reported that hCG levels on the day of OPU for women who correctly administered hCG were 98-161 IU/l. Driscoll et al. (2000) reported a median serum hCG concentration of 117.1 IU/l (range 48 -249) after s.c. administration of recombinant hCG 250 mg, and 83.6 IU/l (range 32 -99) after i.m. administration of 5000 IU urinary hCG. Stevenson and Lashen (2008) in a comprehensive review, offered that hCG levels of 40 mIU/ml should be the cutoff between normal to low hCG levels on the day of OPU. Ndukwe et al. (1996) , trying to predict EFS, stated that serum hCG levels were all ,10 mIU/ml in cases of EFS.
A borderline form of EFS was also suggested in cases in which very few mature or immature oocytes are recovered from several mature follicles (Işik and Vicdan, 2000; Nikolettos et al., 2004; Duru et al., 2007; Desai et al., 2009; Vutyavanich et al., 2010) .
Incidence
The incidence of EFS according to our literature review is 0.045-3.4% (Table III) . These differences may result from different exclusion criteria. In some studies patients with poor response to ovulation induction or premature ovulation were included while in others not. GEFS prevalence is 0-1.1%. Recurrent GEFS cases are scarce. Being such a rare event, recurring EFS escapes even large series and thus might be erroneously regarded as non-existing.
Underlying mechanism
The etiology of GEFS is obscure. Since it was first described, various authors have been skeptical about its existence (Ben-Shlomo et al., 1991; Harrison and Fawzy, 1996; van Heusden et al., 2008) . It was argued that the EFS phenomenon could be explained by premature ovulation, a poor ovarian response or hCG-related faults (Awadalla et al., 1987; Ben-Shlomo et al., 1991; Asch et al., 1992; Greb et al., 1993; Aktas et al., 2005) . Failure to retrieve oocytes, despite correct hCG administration, may be due to low bioavailability which results from variation in the absorption or clearance of hCG (Zegers-Hochschild et al., 1995; Hirshfeld-Cytron and Kim, 2008) , variation in the threshold for follicular response to hCG, variation in the time needed from hCG exposure to maturation of oocytecumulus complexes (Vutyavanich et al., 2010) or intrinsic defects in the biological activity of hCG preparation (Zegers-Hochschild et al., 1995) . Supporting the hypothesis that ovarian low availability of hCG is a cause of EFS, was a case of unilateral EFS due to ovarian torsion occurring between the time of hCG administration and follicular aspiration. Oocytes were aspirated from the unaffected ovary (Stefunidis et al., 2002) . Other etiologies have been suggested, including ovarian aging (Ben-Shlomo et al., 1991; Greb et al., 1993; Lorusso et al., 2005) , dysfunctional folliculogenesis due to increased apoptosis and follicular atresia (Desai et al., 2009) , defective granulosa cell function (Zreik et al., 2000) , faulty oocyte development and maturation (La Sala et al., 1991; Bustillo, 2004; Kourtis et al., 2004; Inan et al., 2006; Duru et al., 2007) , strong attachment of cumulus cell complexes to the follicular wall, dysfunctional ovulation induction (Tsuiki et al., 1988; Khalaf et al., 2000) ora genetic defect (Papier et al., 2000; Onalan et al., 2003; Vujisic et al., 2005; Yariz et al., 2011) . Tsuiki et al. (1988) showed high E 2 and androstendione levels and low progesterone levels in follicular fluid from a patient with EFS. Low levels of progesterone and high levels of testosterone were also reported by Phocas et al. (1992) although they reported low levels of E 2 as well (Tsuiki et al., 1988; Phocas et al., 1992) . Gene expression of granulosa cells from a patient with recurrent EFS was significantly altered compared with a control. The most prominent effect was demonstrated in genes involved in metabolism, cellular processes and apoptosis. The authors suggested that the increased apoptotic gene expression and reduction in transcripts whose products are responsible for proper follicular growth is the cause of EFS in that patient (Inan et al., 2006) . A possible mechanism is that the oocytes are actually lost during late folliculogenesis due to apoptosis. Recently a novel mutation in the LH/choriogonadotropon receptor was identified in two sisters with GEFS (Yariz et al., 2011) . Borderline cases of EFS led us to suspect a defect in the process that results in oocyte maturation and cumulus cell expansion.
Therapeutic approach
Patients with EFS present a challenge to the treating physician. No single treatment is universally effective. Some authors, relying on the low frequency of recurrence, recommend repeating the standard ART cycle, regardless of the treatment protocol (Ben-Shlomo et al., 1991) . Since in most EFS cases, down-regulation was achieved by GnRH agonist (possibly presenting the higher prevalence of agonist over antagonist in ART cycles), shifting from an agonist to antagonist protocol was suggested (Krishna et al., 2008) . In cases where no oocytes are aspirated from one ovary and hCG levels are low, some have suggested readministering hCG from a different batch and aspirating the second ovary (Khalaf and Braude, 1997; Ndukwe et al., 1997; Awonuga et al., 1998; Quintans et al., 1998; Evbuomwan et al., 1999; Esposito and Patrizio, 2000; Papier et al., 2000; Reichman et al., 2010) or even reaspirating the same follicles (Meniru and Craft, 1997; Hassan et al., 1998; Snaifer et al., 2008) . Others suggested changing the hCG from a urinary to a recombinant preparation (Peñarrubia et al., 1999) . Hourvitz et al. (2010) presented two women with EFS who were successfully treated with in vitro maturation.
The two treatment remedies that were used in the case presented here, and thus discussed thoroughly, are using GnRH agonist for final oocyte maturation (Lok et al., 2003) and prolonging the interval between ovulation triggering and OPU (Uygur et al., 2003) .
GnRH agonist for triggering final oocyte maturation
hCG has long been used as a surrogate for the LH surge. Later on, it was demonstrated that ovulation triggering may be achieved by GnRH agonist (Shalev et al., 1994; Fauser et al., 2002; Griesinger et al., 2006) . Among the possible advantages of GnRH agonist for final oocyte maturation is the simultaneous induction of an FSH surge (Gonen et al., 1990; Fauser et al., 2002) . The role of the natural mid-cycle FSH surge is not fully clear. FSH was reported to induce LH receptor formation in luteinizing granulosa cells, promote oocyte nuclear maturation and cumulus expansion (Byskov et al., 1997; Humaidan et al., 2011) . FSH also has a role in keeping the gap junctions open between the oocyte and cumulus cells and thus may have an important role in signaling pathways (Godard et al., 2009; Lamb et al., 2011) . FSH stimulates plasminogen activator activity within granulosa cells, which results in production of plasmin in the follicular fluid (Strickland and Beers, 1976) . Plasmin, in turn, generates active collagenase which disrupts the follicular wall (D'Alessandris et al., 2001; Lamb et al., 2011) . Expansion and dispersion of the cumulus cells allows the oocyte -cumulus cell mass to detach from the follicular wall before ovulation. This process involves synthesis of hyaluronic acid matrix, which is stimulated by FSH (Dell'Aquila et al., 2004) . Adding FSH at the time of the hCG trigger enhances oocyte recovery and improves fertilization (Lamb et al., 2011) . GnRH receptors have been identified in a wide variety of human tissues including pre-ovulatory granulosa cells. Mammalian oocytes remain at prophase of first meiosis from birth until the gondotropin surge at puberty. During this long period, intra oocyte cAMP and cGMP prevents oocyte meiosis resumption. The cGMP level decreases in response to LH and meiosis resumes (Sun et al., 2009) . It was demonstrated that peripheral GnRH receptor activation leads to a decrease in the intracellular cAMP level. GnRH induces transcription of several genes that are involved in follicular rupture and oocyte maturation . The FSH surge and the direct action of the agonist on the ovarian GnRH receptor might explain the favorable results in the eighth cycle in our patient. One can speculate that, for an unknown reason, the LH path is blocked in the patient and the GnRH agonist activates a different path.
Prolonging the interval between ovulation triggering and OPU
In a natural cycle, the onset of LH surge occurs 34-36 h prior to follicular rupture (Hoff et al., 1983) . Similarly, administering exogenous hCG causes follicular rupture after 37 h (Edwards and Steptoe, 1975) . Resumption of meiosis begins 18 h after the onset of the LH surge (Seibel et al., 1982) . LH concentration must be maintained above a threshold for 14-27 h in order to maximize oocyte maturation (Zelinski-Wooten et al., 1992) . Follicular rupture and oocyte maturation are time-dependent processes, with different times needed in different patients. It might be hypothesized that cumulus expansion which allows the oocyte to detach from the follicular wall also requires longer time periods in certain patients. In these cases, EFS may result when aspiration takes place 34 h after hCG administration.
Summary and conclusions
The case presented here demonstrates the existence of a GEFS. The patient was obviously not a low responder since E 2 levels were consistently high after stimulation and many follicles could be visualized. She correctly administered hCG, as was demonstrated by positive hCG in her serum. We cannot exclude anomalous absorption or clearance as the cause of the slightly low serum hCG levels in our patient, but because the hCG levels were higher than those described in connection to EFS, we think another reason should be sought. In the index cycle two treatment options were combined, using GnRH agonist for final oocyte maturation and prolonging the time between ovulation triggering and OPU. It is impossible to differentiate which of the two strategies yielded the desired outcome. Adding hCG 34 h prior to the OPU was most likely not the reason for the successful recovery, in light of the prior multiple failures with this regimen although one cannot reject that combining hCG with GnRH agonist caused the desired effect. It can also not be excluded that the 29 months, that passed between prior treatments and the successful treatment, influenced the outcome. In other words, EFS may be self-limiting phenomena.
We assert that GEFS does exist and submit this case as the proof. We argue, however, that EFS is a misnomer since the follicles are not actually empty, but rather that the oocytes are not aspirated or identified utilizing standard ART methods. EFS may represent a syndrome of impaired granulosa cell function, in which oocyte meiotic maturation is not resumed, cumulus expansion does not ensue and the immature oocyte -cumulus complexes are resistant to follicular aspiration. In the case presented here, prolonging the interval between ovulation triggering and OPU and inducing ovulation using GnRH agonist resulted in aspiration of mature oocytes, pregnancy and delivery. The concealed variation that caused our patient to be resistant to the common IVF regimen, yet sensitive to a novel one, remains a mystery.
